Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006;23(1):55-63.
doi: 10.1007/s10585-006-9017-y. Epub 2006 Jul 7.

Heparanase expression and TrkC/p75NTR ratios in human medulloblastoma

Affiliations

Heparanase expression and TrkC/p75NTR ratios in human medulloblastoma

Neeta D Sinnappah-Kang et al. Clin Exp Metastasis. 2006.

Abstract

Medulloblastoma (MB), the most devastating and common brain tumor in children, is highly invasive and extremely difficult to treat. Identifying the properties of MB tumors that cause them to invade and metastasize is therefore imperative for the development of novel treatments. We performed investigations to elucidate prognostic implications of heparanase (HPSE-1) and TrkC/p75(NTR) expression in MB using formalin-fixed, paraffin-embedded (FFPE) MB clinical specimens from children aged 1-19 years. Expressions of p75(NTR) and HPSE-1 correlated with each other (Pearson's correlation R = 0.899; P < 0.0001; R (2) = 81%; n = 14). In addition, TrkC:p75(NTR) ratios correlated with MB meningeal spread (R = 0.608; P = 0.0212; R (2) = 37%; n = 14). Secondly, using antibodies specific to TrkC and HPSE-1, we carried out immunohistochemistry (IHC) on 22 human MB tissue samples. IHC reaction scores revealed a significant expression of HPSE-1 in 76% of MB tissues from children aged 3 years and older (P = 0.0490; n = 17) while TrkC immunoreactivity was detected in 71% of these patient samples. Of note, TrkC was significantly present in 100% of MB female patients (P = 0.0313; n = 6). These studies support the role of p75(NTR) and HPSE-1 as two novel molecular determinants involved in the biology and clinical progression of MB.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Cancer Res. 2003 Nov 1;9(14 ):5127-36 - PubMed
    1. Int J Oncol. 2005 Sep;27(3):617-26 - PubMed
    1. Trends Mol Med. 2005 Jan;11(1):17-22 - PubMed
    1. J Neurooncol. 1994;18(2):111-21 - PubMed
    1. Oncogene. 2001 Aug 16;20(36):5033-42 - PubMed

Publication types

MeSH terms

LinkOut - more resources